Skip to main content

Primary HPV Screening Intervals Could Be Extended

Medically reviewed by Carmen Pope, BPharm. Last updated on May 26, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 24, 2024 -- Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) eight years after negative HPV screening comparable to risk after three years in cytology cohorts, according to a study published online May 22 in Cancer Epidemiology, Biomarkers & Prevention.

Anna Gottschlich, Ph.D., M.P.H., from the BC Women's Hospital and Health Services in Vancouver, British Columbia, Canada, and colleagues conducted a longitudinal cohort study involving women and individuals with a cervix (WIC) who received one to two negative HPV screens (5,546 in the HPV1 cohort; 6,624 in the HPV2 cohort) and WIC with one to two normal cytology results (782,297 in the BCS1 cohort; 673,778 in the BCS2 cohort). Participants were followed for 14 years.

The researchers found that after eight years, the cumulative risks for CIN2+ were 3.2 and 2.7 per 1,000 in HPV1 and HPV2, respectively. This was comparable to the cytology cohort risk after three years (3.3 and 2.5 per 1,000 in BCS1 and BCS2, respectively). After 10 years, the cumulative risk for CIN2+ was low in the HPV cohorts (4.7 and 3.9 per 1,000 in HPV1 and HPV2, respectively).

"These findings should provide assurance that the five-year interval recommended for HPV screening is even safer than the three-year interval for cytology screening," Gottschlich said in a statement.

Two authors disclosed ties to the pharmaceutical industry; one has a patent registered on DNA methylation markers for early detection of cervical cancer.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2024

Read this next

Survey Reveals Common Misconceptions About Human Papillomavirus

TUESDAY, March 11, 2025 -- The majority of people are unaware that the human papillomavirus (HPV) is more common among men and is associated with rising rates of cancers that...

2008 to 2022 Saw Declines in Cervical Precancers in Women Aged 20 to 24 Years

TUESDAY, March 4, 2025 -- From 2008 to 2022, there were considerable decreases in the rates of cervical intraepithelial neoplasia (CIN) grades 2 to 3 and adenocarcinoma in situ...

Therapeutic Vaccine Shows Preliminary Safety, Effectiveness for HPV16+ Cervical Precancerous Condition

THURSDAY, Jan. 30, 2025 -- For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical intraepithelial neoplasia grade 3 (CIN3), vaccination with a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.